296 related articles for article (PubMed ID: 17720067)
1. In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac.
Walters T; Raizman M; Ernest P; Gayton J; Lehmann R
J Cataract Refract Surg; 2007 Sep; 33(9):1539-45. PubMed ID: 17720067
[TBL] [Abstract][Full Text] [Related]
2. Re: Pharmacokinetics and pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac.
Bucci FA; Waterbury LD
J Cataract Refract Surg; 2008 Aug; 34(8):1226; author reply 1226-7. PubMed ID: 18655957
[No Abstract] [Full Text] [Related]
3. A randomized comparison of to-aqueous penetration of ketorolac 0.45%, bromfenac 0.09% and nepafenac 0.1% in cataract patients undergoing phacoemulsification.
Bucci FA; Waterbury LD
Curr Med Res Opin; 2011 Dec; 27(12):2235-9. PubMed ID: 21992076
[TBL] [Abstract][Full Text] [Related]
4. Prostaglandin E2 inhibition of ketorolac 0.45%, bromfenac 0.09%, and nepafenac 0.1% in patients undergoing phacoemulsification.
Bucci FA; Waterbury LD
Adv Ther; 2011 Dec; 28(12):1089-95. PubMed ID: 22105509
[TBL] [Abstract][Full Text] [Related]
5. Prostaglandin E2 inhibition and aqueous concentration of ketorolac 0.4% (acular LS) and nepafenac 0.1% (nevanac) in patients undergoing phacoemulsification.
Bucci FA; Waterbury LD; Amico LM
Am J Ophthalmol; 2007 Jul; 144(1):146-7. PubMed ID: 17601444
[TBL] [Abstract][Full Text] [Related]
6. Vitreous nonsteroidal antiinflammatory drug concentrations and prostaglandin E2 levels in vitrectomy patients treated with ketorolac 0.4%, bromfenac 0.09%, and nepafenac 0.1%.
Heier JS; Awh CC; Busbee BG; Waterbury LD; Daniel P; Stoller GL; Cleary TS
Retina; 2009 Oct; 29(9):1310-3. PubMed ID: 19934822
[TBL] [Abstract][Full Text] [Related]
7. Comparison of ketorolac 0.4% and bromfenac 0.09% at trough dosing: aqueous drug absorption and prostaglandin E2 levels.
Bucci FA; Waterbury LD
J Cataract Refract Surg; 2008 Sep; 34(9):1509-12. PubMed ID: 18721711
[TBL] [Abstract][Full Text] [Related]
8. Nepafenac: an ophthalmic nonsteroidal antiinflammatory drug for pain after cataract surgery.
Jones BM; Neville MW
Ann Pharmacother; 2013 Jun; 47(6):892-6. PubMed ID: 23715071
[TBL] [Abstract][Full Text] [Related]
9. Aqueous prostaglandin E(2) of cataract patients at trough ketorolac and bromfenac levels after 2 days dosing.
Bucci FA; Waterbury LD
Adv Ther; 2009 Jun; 26(6):645-50. PubMed ID: 19568702
[TBL] [Abstract][Full Text] [Related]
10. Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium.
Waterbury LD; Silliman D; Jolas T
Curr Med Res Opin; 2006 Jun; 22(6):1133-40. PubMed ID: 16846546
[TBL] [Abstract][Full Text] [Related]
11. Effects of topical indomethacin, bromfenac and nepafenac on lipopolysaccharide-induced ocular inflammation.
Bucolo C; Marrazzo G; Platania CB; Romano GL; Drago F; Salomone S
J Pharm Pharmacol; 2014 Jul; 66(7):954-60. PubMed ID: 24697218
[TBL] [Abstract][Full Text] [Related]
12. Ocular penetration and anti-inflammatory activity of ketorolac 0.45% and bromfenac 0.09% against lipopolysaccharide-induced inflammation.
Waterbury LD; Galindo D; Villanueva L; Nguyen C; Patel M; Borbridge L; Attar M; Schiffman RM; Hollander DA
J Ocul Pharmacol Ther; 2011 Apr; 27(2):173-8. PubMed ID: 21351868
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and efficacy of topically applied nonsteroidal anti-inflammatory drugs in retinochoroidal tissues in rabbits.
Kida T; Kozai S; Takahashi H; Isaka M; Tokushige H; Sakamoto T
PLoS One; 2014; 9(5):e96481. PubMed ID: 24796327
[TBL] [Abstract][Full Text] [Related]
14. Distribution of topical ocular nepafenac and its active metabolite amfenac to the posterior segment of the eye.
Chastain JE; Sanders ME; Curtis MA; Chemuturi NV; Gadd ME; Kapin MA; Markwardt KL; Dahlin DC
Exp Eye Res; 2016 Apr; 145():58-67. PubMed ID: 26474497
[TBL] [Abstract][Full Text] [Related]
15. Comparative effects of the nonsteroidal anti-inflammatory drug nepafenac on corneal sensory nerve fibers responding to chemical irritation.
Acosta MC; Luna C; Graff G; Meseguer VM; Viana F; Gallar J; Belmonte C
Invest Ophthalmol Vis Sci; 2007 Jan; 48(1):182-8. PubMed ID: 17197531
[TBL] [Abstract][Full Text] [Related]
16. Ocular permeation and inhibition of retinal inflammation: an examination of data and expert opinion on the clinical utility of nepafenac.
Lindstrom R; Kim T
Curr Med Res Opin; 2006 Feb; 22(2):397-404. PubMed ID: 16466612
[TBL] [Abstract][Full Text] [Related]
17. Effect of topical ketorolac 0.4%, nepafenac 0.1%, and bromfenac 0.09% on postoperative inflammation using laser flare photometry in patients having phacoemulsification.
Sahu S; Ram J; Bansal R; Pandav SS; Gupta A
J Cataract Refract Surg; 2015 Oct; 41(10):2043-8. PubMed ID: 26703278
[TBL] [Abstract][Full Text] [Related]
18. Concentration and dosing of ketorolac versus bromfenac.
Gayton J
J Cataract Refract Surg; 2009 Jul; 35(7):1319; author reply 1320. PubMed ID: 19545832
[No Abstract] [Full Text] [Related]
19. The effects of nepafenac and amfenac on retinal angiogenesis.
Yanni SE; Clark ML; Yang R; Bingaman DP; Penn JS
Brain Res Bull; 2010 Feb; 81(2-3):310-9. PubMed ID: 19897019
[TBL] [Abstract][Full Text] [Related]
20. Prostaglandin E
Acar U; Acar DE; Tanriverdi C; Acar M; Ozdemir O; Erikci A; Ornek F
Ocul Immunol Inflamm; 2017 Jun; 25(3):323-327. PubMed ID: 26765265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
